3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid, Acute
1
Carcinoma, Renal Cell
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
7
fludarabine phosphate
6
fludarabine
5
Immunotherapy, Adoptive
3
blinatumomab
2
Cytarabine
2
Azacitidine
2
AP 1903 reagent
2
venetoclax
1
tisagenlecleucel
1
ruxolitinib
1
relugolix
1
pulrodemstat besilate
1
niraparib
1
nilotinib
1
enzalutamide
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Rituximab
1
Radiotherapy
1
NKTR-255
1
Melphalan
1
Injections
1
Imatinib Mesylate
1
GNKG168
1
Dasatinib
1
Cetuximab
1
CTL019 chimeric antigen receptor
1
CD3 Complex
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasm, Residual
×
CD3 Complex
×
Clear all
NCT03038230
2025-04-06
MCLA-117 in Acute Myelogenous Leukemia
Merus B.V.
Phase 1
Terminated
80 enrolled